641 related articles for article (PubMed ID: 30075873)
1. Cardiac and Renal Effects of Sodium-Glucose Co-Transporter 2 Inhibitors in Diabetes: JACC State-of-the-Art Review.
Zelniker TA; Braunwald E
J Am Coll Cardiol; 2018 Oct; 72(15):1845-1855. PubMed ID: 30075873
[TBL] [Abstract][Full Text] [Related]
2. Diabetes mellitus: Cardiovascular and renal benefits of SGLT2 inhibition: insights from CANVAS.
Vallon V; Thomson SC
Nat Rev Nephrol; 2017 Sep; 13(9):517-518. PubMed ID: 28781373
[No Abstract] [Full Text] [Related]
3. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
4. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
5. Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective.
Silva Dos Santos D; Polidoro JZ; Borges-Júnior FA; Girardi ACC
Am J Physiol Cell Physiol; 2020 Feb; 318(2):C328-C336. PubMed ID: 31721613
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
Zelniker TA; Braunwald E
J Am Coll Cardiol; 2020 Feb; 75(4):422-434. PubMed ID: 32000955
[TBL] [Abstract][Full Text] [Related]
7. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
Lee S
Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
[TBL] [Abstract][Full Text] [Related]
8. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments.
Garcia-Ropero A; Badimon JJ; Santos-Gallego CG
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1287-1302. PubMed ID: 30463454
[TBL] [Abstract][Full Text] [Related]
9. Clinical Benefit of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors: JACC State-of-the-Art Review.
Zelniker TA; Braunwald E
J Am Coll Cardiol; 2020 Feb; 75(4):435-447. PubMed ID: 32000956
[TBL] [Abstract][Full Text] [Related]
10. A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors.
Brown E; Rajeev SP; Cuthbertson DJ; Wilding JPH
Diabetes Obes Metab; 2019 Apr; 21 Suppl 2():9-18. PubMed ID: 31081592
[TBL] [Abstract][Full Text] [Related]
11. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
[No Abstract] [Full Text] [Related]
12. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.
Verma S; McMurray JJV
Diabetologia; 2018 Oct; 61(10):2108-2117. PubMed ID: 30132036
[TBL] [Abstract][Full Text] [Related]
13. SGLT2 inhibition and heart failure-current concepts.
Custodio JS; Duraes AR; Abreu M; Albuquerque Rocha N; Roever L
Heart Fail Rev; 2018 May; 23(3):409-418. PubMed ID: 29704192
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Nat Rev Endocrinol; 2020 Oct; 16(10):556-577. PubMed ID: 32855502
[TBL] [Abstract][Full Text] [Related]
15. Effects of sodium glucose cotransporter 2 inhibitors on mineral metabolism in type 2 diabetes mellitus.
Vinke JSJ; Heerspink HJL; de Borst MH
Curr Opin Nephrol Hypertens; 2019 Jul; 28(4):321-327. PubMed ID: 30958403
[TBL] [Abstract][Full Text] [Related]
16. [In patients with type 2 diabetes and diabetic nephropathy with albuminuria, what is the effect of SGLT2 inhibitor canagliflozin on renal and cardiovascular outcomes?].
Lanthier L; Huard G; Plourde MÉ; Cauchon M
Rev Med Interne; 2020 Jan; 41(1):67-68. PubMed ID: 31812446
[No Abstract] [Full Text] [Related]
17. Inhibition of the Sodium-Proton Antiporter (Exchanger) is a Plausible Mechanism of Potential Benefit and Harm for Drugs Designed to Block Sodium Glucose Co-transporter 2.
McCullough PA; Kluger AY; Tecson KM; Barbin CM; Lee AY; Lerma EV; Rosol ZP; Kluger SL; Rangaswami J
Rev Cardiovasc Med; 2018 Jun; 19(2):51-63. PubMed ID: 31032603
[TBL] [Abstract][Full Text] [Related]
18. Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis.
Wu JH; Foote C; Blomster J; Toyama T; Perkovic V; Sundström J; Neal B
Lancet Diabetes Endocrinol; 2016 May; 4(5):411-9. PubMed ID: 27009625
[TBL] [Abstract][Full Text] [Related]
19. Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.
Usman MS; Siddiqi TJ; Memon MM; Khan MS; Rawasia WF; Talha Ayub M; Sreenivasan J; Golzar Y
Eur J Prev Cardiol; 2018 Mar; 25(5):495-502. PubMed ID: 29372664
[TBL] [Abstract][Full Text] [Related]
20. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
